News archive

Older people with a genetic risk of Alzheimer's disease did not experience the expected increase in cognitive decline and dementia risk if they consumed relatively large amounts of meat. This is shown in a new study from Karolinska Institutet published in JAMA Network Open. The results may contribute to the development of more individually tailored dietary advice.

A simple combination of daily physical exercise and protein-rich nutritional drinks appears to offer significant health benefits for people with dementia. In a new study from Karolinska Institutet, not only did the participants' physical ability improve, but after three months the researchers also saw signs that they were able to manage more everyday tasks themselves. The study is published in the journal Alzheimer's and Dementia.

People with lower kidney function may have higher levels of several blood markers often used in research on Alzheimer’s disease and related dementias. This is shown in a new systematic review and meta‑analysis published in The Journal of the American Society of Nephrology.

How hereditary Alzheimer’s disease develops in its early stages depends on which genetic mutation a person carries. This is shown in a new study from Karolinska Institutet, published in the journal Translational Psychiatry.

Bill Gates visited Karolinska Institutet and Karolinska University Hospital last Friday at his own initiative to discuss the latest advances in Swedish Alzheimer’s research, a field that interests him and that he supports.

Older adults with reduced kidney function show higher levels of Alzheimer’s-related biomarkers in the blood, but are not more likely to develop dementia, according to a new study from Karolinska Institutet.

How do everyday health issues affect new blood tests for Alzheimer’s disease? A study from Karolinska Institutet, in Alzheimer's & Dementia, suggests that factors like kidney function, cholesterol, and diabetes can influence some of these biomarkers—though the most promising marker remains reliable.

Researchers at Karolinska Institutet in Sweden and the RIKEN Center for Brain Science in Japan have identified two receptors in the brain that control the breakdown of amyloid beta, a substance that accumulates in Alzheimer’s disease. According to the researchers, the study could pave the way for future drugs that are both safer and cheaper than current antibody treatments.

The Aging Research Center (ARC) was established in the year 2000, at a time when geriatric research was still in its infancy and little was known about dementia-related diseases. This happened during a period when politicians and decision-makers began to take an interest in the growing ageing population and the challenges that were becoming apparent in healthcare and social care as a result.

Hi Francesca Eroli, doctoral student at the Division of Neurogeriatrics. On November 7 november you will defend your thesis ”Toward precision medicine : sex-specific effects of multi-drug therapies in mouse models of aging and Alzheimer's pathology” What is the main focus of the thesis?

It is exciting to announce that NVS has signed a Memorandum of Understanding (MoU) with IDAC for academic exchange and to further strengthen the academic ties between the two institutions. The MoU was signed on August 11th, 2025, by Professor Maria Ankarcrona, Head of Department, NVS and Professor Kozo Tanaka, Director of IDAC.

A new international study led by researchers at Karolinska Institutet demonstrates that it is possible to detect subtle changes in the brain and identify early signs of hereditary frontotemporal dementia using advanced brain imaging techniques. The study has recently been published in Molecular Psychiatry.

On September 2, 2025, seven physicians, five occupational therapists, and five physiotherapists were awarded diplomas by H.M. The Queen during a formal ceremony at Drottningholm Court Theatre. The ceremony marked the completion of the Master's courses in dementia care developed by Karolinska Institutet in close collaboration with Stiftelsen Silviahemmet. The participants may now use the titles Silvia Physician, Silvia Occupational Therapist, and Silvia Physiotherapist.

Shireen Sindi at NVS and her team have been awarded this major award. It is the first time an applicant from Karolinska Institutet (KI) has received such a large award from Wellcome Leap, with whom KI has had an agreement since 2021.

A protein from the bacterium Helicobacter pylori has been shown to block the formation of harmful protein aggregates - known as amyloids - that are linked to Alzheimer's, Parkinson's and type 2 diabetes, among other diseases, and bacterial infections. This is the result of a new study published in the journal Science Advances.

Hi Vilma Alanko, doctoral student at the Division of Clinical Geriatrics. On June 13 you will defend your thesis ”Translational studies on biological signatures, risk profiles, and prevention of dementia.” What is the main focus of the thesis?

The partnership between Johnson & Johnson Innovative Medicine (J&J) and Karolinska Institutet (KI) marks this year a decade of joint initiatives for promoting the development of tomorrow’s therapies. This long-standing collaboration between industry and academy has given rise to significant scientific advances in several fields of medicine.

The 2025 Svedberg Prize is awarded to Michael Landreh, Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet, "for the development and innovative use of mass spectrometric tools that reveal hidden protein interactions."

Researchers at Karolinska Institutet have demonstrated how specific biomarkers in the blood can predict the development of dementia up to ten years before diagnosis, among older adults living independently in the community.

Certain widely used drug combinations may either slow down or worsen the progression of Alzheimer’s disease, but their effects differ between sexes. A new study from Karolinska Institutet, published in the leading journal Alzheimer’s & Dementia, highlights these important findings.

New research suggests that antidepressants can accelerate cognitive decline in people with dementia. At the same time, some drugs appear to be less harmful than others, which can help doctors make better treatment decisions, according to the study published in BMC Medicine.

A new Swedish study has, for the first time, shown a link between rheumatoid arthritis (RA) and cognitive decline in dementia patients. The study, published in the scientific journal Neurology, emphasizes the importance of careful monitoring and management to prevent cognitive decline.

On 30 January, a symposium on dementia was held in honour of HM Queen Silvia at Karolinska Institutet. The event was part of the "experience gift" that KI presented in connection with the Queen’s 80th birthday.

Using an AI tool, researchers at Karolinska Institutet have analysed brain images from 70-year-olds and estimated their brains’ biological age. They found that factors detrimental to vascular health, such as inflammation and high glucose levels, are associated with an older-looking brain, while healthy lifestyles were linked to brains with a younger appearance. The results are presented in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

How are emerging plasma biomarkers related to the diagnostic tests currently used in clinical routines? And does the earlier evidence from highly selective research cohorts translate to the heterogeneous real-world data? Researchers at Karolinska Institutet have sought to answer these questions in a study published in eBioMedicine with Dr. Marina Bluma from the Department of Neurobiology, Care Sciences and Society as the first author.

The Mats Paulsson Foundations award Jan Johansson, professor at the Department of Medicine, Huddinge, Karolinska Institutet, SEK 10 million for research into new innovative treatment methods for Alzheimer's disease. The aim of the research project is to create a new drug that can achieve a breakthrough in the treatment of the most common dementia disease.

The Swedish Brain Foundation has awarded its grants. NVS received five research grants and one scholarship.

The Swedish Society of Medicine (SLS) awards Professor Lars-Olof Wahlund, Karolinska Institutet, the Bengt Winblad Prize 2024. The prize honors outstanding contributions in Alzheimer’s research, and Lars-Olof Wahlund is seen as a pioneer in MRI imaging of the brain.

Some of the world’s most prominent Alzheimer’s researchers congregated recently in Stockholm for the tenth anniversary of the prestigious Goodes Prize. The programme included a seminar day and a study visit to Karolinska Institutet followed by a social event in Stockholm City Hall.

A groundbreaking study from Karolinska Institutet, recently published in the journal Molecular Psychiatry offers new insights into the progression of Alzheimer’s disease (AD). The research reveals critical differences in the progression of memory loss based on the presence of specific proteins in the brain.

Karolinska Institutet has discovered that an already registered antidepressant, duloxetine, may also have positive effects on memory and cognitive functions in the elderly.

Per Nilsson, docent at the Division of Clinical Geriatrics, receives this amount together with Evandro Fang at the University of Oslo. Additionally, the funding is 200,000 USD per year for two years with the possibility of extension.

He receives the grant for the project ‘Preclinical Evaluation of Potential Cholinergic PET Imaging Tracers’ and it is valid for a three-year period.

Hi Jasper Holleman, doctoral student at the Division of Clinical Geriatrics. On June 18 you will defend your thesis "Novel biomarkers associated with stress : from normal aging to Alzheimer's disease ". What is the main focus of the thesis?

Hi Johanna Mayer, doctoral student at the Division of Neurogeriatrics. On June 17 you will defend your thesis "The role of autophagy in Aβ and tau metabolism in Alzheimer’s disease ". What is the main focus of the thesis?

While mentally stimulating activities and life experiences can improve cognition in memory clinic patients, stress undermines this beneficial relationship. This is according to a new study from Karolinska Institutet published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

Minister for Health Care Acko Ankarberg Johansson and Minister for Older People and Social Security Anna Tenje recently visited BioClinicum at Karolinska Institutet to learn more about the current status of Alzheimer’s research. "We’re getting closer to being able to devise an effective treatment," says Bengt Winblad, professor at the Department of Neurobiology, Care Sciences and Society, who hosted the visit.

A new study from Karolinska Institutet, published in Brain, reveals a connection between the protein DEK and early neuronal changes in Alzheimer’s disease. Researchers found that lower DEK levels in vulnerable neurons lead to altered neuronal activity and Tau protein accumulation, offering insights into early-stage Alzheimer’s pathology and potential therapeutic targets.

Researchers at Karolinska Institutet have made exciting discoveries about Alzheimer's disease, a common form of dementia affecting millions of people around the world. In a study published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, they have explored the potential of novel synaptic PET-tracer UCB-J as an important early diagnostic biomarker/tool for Alzheimer's disease.

Karolinska Institutet is one of 24 partners in AD-RIDDLE, a collaborative project that aims to increase healthcare providers' ability to diagnose, prevent and treat Alzheimer's disease. The project, supported by, among others, the EU's Innovative Health Initiative (IHI), started in January 2024 and will run for five years.

A new study published in Nature Communications gives insights into the underlying mechanisms of the formation of protein clumps in Alzheimer’s disease. The study, led by researchers from Karolinska Institutet, could pave the way for new treatments for this devastating neurodegenerative disorder.

Karolinska Institutet is part of the AD-RIDDLE consortium, a project dedicated to increasing health professional’s capabilities to detect, diagnose, prevent, and treat Alzheimer’s disease. Funded by the EU Innovative Health Initiative (IHI) and the UK Research and Innovation (UKRI), the project was launched in January 2024, includes 24 partners, and will run over five years.

A new study at the Karolinska Institutet suggests that activation of a certain brain protein can protect women from developing neurodegenerative diseases such as Alzheimer's disease.

Hi Mona-Lisa Malarte, doctoral student at the Division of Clinical Geriatrics. Om January 26 you will defend your thesis ”Tau pathology in Alzheimer's disease and other dementias : translational approach from in vitro autoradiography to in vivo PET imaging”. What is the main focus of the thesis?

Blood fat-lowering statins could slow the progression of Alzheimer's disease, at least for some patients. This is the result of a new study led by Karolinska Institutet published in Alzheimer Research and Therapy. But the researchers are cautious in their interpretations and see the results as a first step in a research journey that may eventually provide the answer.

Dementia diseases cost Swedish society around SEK 80 billion per year. The EU has now awarded funding to the Prominent project, which aims to improve both diagnostics and treatment for these diseases. Karolinska Institutet is responsible for the project in the role of coordinator.

An early phase in the process of developing Alzheimer’s disease is a metabolic increase in a part of the brain called the hippocampus, report researchers from Karolinska Institutet in a study published in Molecular Psychiatry. The discovery opens up for new potential methods of early intervention.

Hi Michael Axenhus, PhD student at the Division of Neurogeriatrics. On October 20 you will defend your thesis ”Characterization of proteins involved in disease progression in Alzheimer disease”, what is the main focus of the thesis?

The prize is awarded annually by the Swedish Society of Medicine (SLS) to a person who has made outstanding contributions to Alzheimer's research. This year the Bengt Winblad Prize is awarded to Laura Fratiglioni, Professor of Medical Epidemiology with a focus on dementia diseases at the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet.

A new study shows that the activation of the brain's immune defense cells, astrocytes, in the early stages of Alzheimer's disease, could be tracked early with a brain PET scanner, and is linked to changes that can be detected in the blood later in the course of the disease. The study has now been published in Molecular Neurodegeneration.